Trump's Foreign Aid Retreat Guts Funding for HIV Treatments, Risking Lives Globally
'People used to sell their land to buy medicines,' she recalled. It wasn't until 2011 that she began antiviral therapy, thanks to free drugs available through the US-funded President's Emergency Plan for AIDS Relief, or Pepfar.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Bluesight introduces ShortageCheck to manage drug inventories in hospitals
Hospital intelligence solutions provider Bluesight has launched ShortageCheck technology designed to assist health systems and hospitals in tracking, forecasting and managing drug inventories. ShortageCheck integrates real-time inventory data, predictive analytics, and collaborative planning tools into a comprehensive platform. This innovation is poised to ensure that caregivers and patients have uninterrupted access to essential medications. Monitoring over 20 real-time market signals, encompassing demand spikes and fulfilment delays, ShortageCheck provides coverage across more than 2,500 acute care facilities across the US. It identifies early warning signs of drug shortages, offering up to a 90-day lead time, with an average of 42 days, allowing healthcare institutions to prepare and adapt their inventory management strategies. By assessing levels of inventory, usage rates along with days-on-hand, the platform offers in-depth insights into the potential impact of each shortage. This enables organisations to evaluate risk, prioritise responses and leverage ShortageCheck's communication tools for cross-team coordination and planning. Bluesight CEO and co-founder Kevin MacDonald said: 'Shortage management has been one of, if not the most critical, pain point for our customers over the last six years. When drug shortages hit without warning, it forces teams to scramble for alternatives, and patient care ultimately suffers. 'With improving health system operations as our top priority, the launch of ShortageCheck marks a significant milestone in ensuring customers have the solutions needed to get ahead of shortages before they hit, preserving labour hours and costs during a time when drug costs are rising, staff shortages persist, and medicare reimbursement changes are on the horizon.' ShortageCheck is part of the hospital intelligence solutions suite of Bluesight, which includes CostCheck, KitCheck, 340BCheck, ControlCheck and PrivacyPro. These tools collectively offer hospitals the capability to restock inventory quicker, reduce drug expenditure, streamline audit preparations, pinpoint drug diversion more effectively, and save time in protecting patient privacy. This January, Bluesight expanded its capabilities by acquiring Protenus, a healthcare compliance analytics platform provider. "Bluesight introduces ShortageCheck to manage drug inventories in hospitals" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
2 hours ago
- Business Wire
Wisdom, the AI-Powered Dental Revenue Cycle Management Platform, Raises $28M to Accelerate Product Innovation and Capitalize on Rapid Growth
SAN FRANCISCO--(BUSINESS WIRE)--AI in revenue cycle management has become top of mind across the healthcare industry, but when it comes to the dental market, dentists are lacking the modern tools used by their medical counterparts. That's the problem that AI-powered dental RCM platform, Wisdom, is on a mission to solve. The company announced today the successful completion of its $21M Series A capital raise led by Permanent Capital Ventures (PCV), a venture capital firm that partners with founders to build go-to-market engines for enterprise scale. Aquiline, a private investment firm specializing in financial services and technology, joined the round, alongside existing investor and Co-Founder, Juxtapose, a leading creation-oriented investment firm. Juxtapose followed their recent $7M Seed investment, reaffirming the firm's commitment to Wisdom's continued growth and innovation. This funding brings Wisdom's total capital raised to $28M since its founding in 2023. The opportunity to use technology to help dentists build and run their businesses more effectively is immense. Share The overwhelming majority of independent practices and small dental groups in America struggle with the administrative burden of running a profitable business, leaving over $20 billion of earned revenue uncollected despite spending billions of dollars on salaries for in-house revenue management. Wisdom, which has already collected hundreds of millions of dollars for its clients and saved them up to 50% of collection costs, takes a highly differentiated approach to administrative workflows by bringing AI agents and human experts together to maximize revenue collections, predictability, transparency and patient satisfaction, thereby freeing dentists and their staff to focus on delivering outstanding patient care. Since its inception, Wisdom has rapidly expanded by combining advanced, proprietary AI-driven technology with US-based billing experts. This unique approach has propelled Wisdom to achieve exceptional client satisfaction, underscored by a consistently high Net Promoter Score of 73 and strong organic growth. Over 50% of Wisdom's signed deals still come through referrals. Wisdom was awarded Top Dental Billing Company by Healthcare Business Review earlier this year and was named a 2025 Dental Innovator Award winner by DentalIQ for its AI-assisted dental billing service. Wisdom is led by CEO Stoyan Kenderov, an accomplished technologist, product leader and executive with over 25 years of success building new products and transforming organizations into customer-obsessed teams that drive growth and profitability, most recently as COO of business payments platform Plastiq. Prior to his time at Plastiq, Stoyan held senior leadership roles at LendingClub, Intuit, Quicken, and many other international technology companies. Stoyan is joined by Wisdom Co-Founder and Chief Dental Billing Officer Ashley Bond, who previously founded and led the award-winning nationwide billing service, Bond Dental Billing. 'We are thrilled to partner with PCV and Aquiline as we continue our mission to transform dental billing and revenue management,' said Kenderov. 'Their proactive approach and expertise in building scalable enterprises align perfectly with our vision to significantly enhance financial outcomes and operational efficiency for dental practices.' PCV's investment in Wisdom reflects the firm's strategy of supporting innovative startups poised for transformational growth. 'Wisdom has created an impressive track record by uniquely integrating AI technologies with deep industry expertise,' said Mike Gamson, Co-Founder and Managing Partner at Permanent Capital Ventures. 'We see immense potential in their ability to scale and redefine revenue management solutions in the dental sector and beyond.' Aquiline has a history of building scaled revenue cycle management businesses, and this investment in Wisdom marks the firm's second investment supporting the dental industry. 'While we continue to see significant innovation across dental, the market is filled with point solutions and generally lacks modern, end-to-end platforms, especially across the rev cycle process,' said Dante La Ruffa, Partner at Aquiline. 'We believe that Stoyan and his team are reimagining the future of dentistry, starting with the key pain points that have historically inhibited dentists from maximizing their time with patients.' This funding will enable Wisdom to further enhance its technology platform, accelerate market expansion, and continue building out its exceptional team to better serve dental offices of all sizes - from private practices to multi-location dental groups across the country. 'The opportunity to use technology to help dentists build and run their businesses more effectively is immense. Stoyan and his team have moved quickly but thoughtfully to build a solution which really moves the needle for dentists while preserving the value of human expertise,' said Andy Stein, Partner at Juxtapose. For more information about Wisdom and its innovative dental billing solutions, please visit About Juxtapose Juxtapose is a creation-oriented investment firm building and funding industry-defining technology companies. Juxtapose's concept development and investment process is focused on multi-decade opportunities in complex industries that leverage the team's expertise in software and technology, human-centered design, commercial strategy, executive talent assessment, and private capital markets. Juxtapose has built and led the financing of companies across software, healthcare, and tech-enabled services that have raised over $1B of external, follow-on private capital. Founded in 2016, Juxtapose now has over $1B AUM. About Permanent Capital Ventures Permanent Capital Ventures is an expansion stage venture capital firm that partners with extraordinary founders building AI application businesses. We lean in with unique go-to-market expertise in the moments after product-market fit has been established to help unlock the path to enterprise scale. About Aquiline Aquiline Capital Partners LP ('Aquiline') is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of June 30, 2025, Aquiline has approximately $13 billion of assets under management across the firm's three strategies in private equity, venture, and credit. Additional information is available on the firm's website: Aquiline Capital Partners LP ('Aquiline') is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of June 30, 2025, Aquiline has approximately $13 billion of assets under management and has deployed approximately $7.4 billion of capital across the firm's three strategies in private equity, venture, and credit.
Yahoo
5 hours ago
- Yahoo
Walmart recalls shrimp over possible radioactive contamination
Certain Great Value raw frozen shrimp products sold at Walmart are being recalled due to possible contamination with Cesium-137, a radioactive isotope, the Food and Drug Administration said Tuesday. The alert follows a notification from U.S. Customs and Border Protection, which detected potential Cs-137 contamination in shipping containers at four US ports. Subsequent testing on frozen shrimp from BMS Foods, an Indonesian distributor, also returned positive results for the radioactive substance. Despite these findings, the FDA confirmed that no contaminated shrimp have entered the US food supply. The FDA continues to advise recalling all BMS Foods products shipped after the company's containers tested positive for Cesium-137, even though the individual products have not shown contamination. The following Great Value brand frozen shrimp products sold at Walmart stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas, and West Virginia should not be eaten: Great Value frozen raw shrimp, lot code: 8005540-1, Best by Date: 3/15/2027 Great Value frozen raw shrimp, lot code: 8005538-1, Best by Date: 3/15/2027 Great Value frozen raw shrimp, lot code: 8005539-1, Best by Date: 3/15/2027 Consumers who have purchased these products should throw them away immediately. The FDA has also imposed a ban on all future imports from BMS Foods until the company addresses the conditions that led to the contamination risk. According to the U.S. Environmental Protection Agency, exposure to significant amounts of Cs-137 can cause burns, acute radiation sickness, and, in severe cases, death. Solve the daily Crossword
